Using albumin-to-globulin ratio and PNI to predict lupus activity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will measure albumin and globulin levels to calculate AGR and compute the prognostic nutritional index, then correlate those markers with clinical signs and routine laboratory measures of SLE activity. Adults who meet the SLICC classification for SLE and matched controls will be enrolled at Sohag University hospitals. Key exclusions include other chronic inflammatory or autoimmune diseases, recent infection, malignancy, pregnancy or lactation, and significant liver or renal insufficiency to reduce confounding. The aim is to develop a simple, non-invasive, and low-cost marker panel that could complement existing clinical and laboratory assessments of disease activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* · Age ≥ 18 years.

  * Both sexes.
  * Patients diagnosed with SLE who fulfilling the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria and matched controls.

Exclusion Criteria:

* Co-existing chronic inflammatory or autoimmune diseases.
* Age \<18 years
* Malignancy.
* Pregnancy or lactation.
* Chronic liver or renal insufficiency.
* Malignant hematologic diseases.
* Active hepatitis.
* Acute infection within the previous four weeks

Where it's running

• Sohag University hospitals
  Sohag, Egypt Recruiting

Study contacts

• Study coordinator: Hala A Hamid, Master
• Email: Hala.hamed@med.sohag.edu.eg
• Phone: 20 01122385665

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing interleukin 23 in patients with systemic lupus erythematosus and lung disease

  This study is testing the levels of a protein called interleukin 23 in people with systemic lupus erythematosus and lung disease to see how it might affect their treatment.

  Recruiting at 2 sites Sohag University · Sohag and 1 other locations · NCT06713187

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Home urine testing for people with lupus

  Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.

  Recruiting NYU Langone Health · New York, New York · NCT07823478

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.